EGFR and nasopharyngeal carcinoma: In a recent Phase I/II study (NCT02507154), Lim and co-workers assessed the safety and efficacy of combining cetuximab (anti-EGFR) with autologous expanded NK cells in EGFR-positive, recurrent and/or metastatic NPC patients who had failed at least two prior lines of chemotherapy.